TBRG stock has nearly doubled from its April lows, yet the short position is quietly unwinding — making next week's earnings the moment where the revised story gets its first real test.
The price move is the most striking feature. TBRG closed Friday at $25.83, up 49% over the past month, after trading as low as $14 in early April. That kind of gap-up from multi-year lows typically forces reassessment across the holder base — and the short community has been one of the first to adjust. Short interest has fallen every session this week. It now accounts for roughly 6.6% of the free float, down from a peak of around 8.6% in mid-April and 7.5% a month ago. In absolute share terms, the position has shrunk nearly 15% over the past month.
The lending market confirms that bears are backing away without much friction. Cost to borrow has eased to 0.46% — a modest annual rate, down 17% on the week — and availability is wide open relative to where it has been. Borrow utilisation has roughly halved from its recent high near 29%, and is now running around 15%. None of this signals short-squeeze pressure; if anything, the data shows an orderly retreat rather than a panicked cover. The ORTEX short score has also dropped steadily this month, falling from the mid-50s ten days ago to 45.6 today — moving the stock into neutral short-positioning territory.
Options traders are slightly less relaxed. The put/call ratio moved to 0.68 on Friday — above its 20-day average of 0.55, though the z-score of 0.5 keeps it short of genuinely cautious territory. The biggest defensive tilt in options occurred in late April, when PCR briefly crossed 1.0 while the stock was still far below current levels. Since then, as the price has recovered, calls have reasserted themselves. The current reading reflects a modest hedge rather than an active bear position.
The Street is divided on how to frame the new price level. Two analysts downgraded TBRG on April 24, both to Neutral/Hold — Cantor Fitzgerald and Freedom Capital Markets both lowered their ratings while actually raising targets to $26.25. That is a textbook "upgrade the number, downgrade the conviction" move: the Street acknowledges the rally but sees limited upside from here. The consensus sits at six Holds and zero Buys, with a mean target of $26.67 — roughly where the stock is trading now. The valuation picture is modest, with EV/EBITDA near 6.6x and a PE around 9.7x. EPS momentum over 90 days ranks in the 81st percentile, suggesting the underlying profit trajectory still has supporters even if analysts are hesitant to endorse the stock at current levels. Benzinga's bull framework points to expanding gross margins in both Patient Care and Financial Health; the bear case highlights a steep drop in new bookings across both segments.
Institutional positioning adds an interesting undercurrent. The top five holders collectively own over 39% of shares, led by L6 Holdings at 14.2% and Ocho Investments at 7.4% — both holding steady with no recent changes. Rorema Beheer B.V., a mid-size Dutch fund, cut its position by around 318,000 shares as of late April, one of the few active sellers among the reported top holders. BlackRock and Vanguard made small additions. The concentrated ownership means any meaningful rotation by the top holders reads immediately into the share price.
Insider activity from mid-March is also worth noting for context. The CEO, CFO, and General Counsel all sold small parcels at around $17.31–$17.59 in March — routine-looking sales in value terms (the CEO's sale totalled roughly $104,000), but notable because those prices are now 47% below where the stock closed Friday. The last Q4 earnings release triggered an 11.8% one-day gain and a 23.6% five-day move, underscoring how sharply TBRG can reprice around a print.
Q1 results land on May 14. The key question is whether organic revenue growth in the Financial Health segment can sustain the mid-single-digit trajectory analysts were counting on before the bookings weakness caught their attention — and whether management addresses the booking decline directly enough to justify what has become a near-doubled stock price in five weeks.
See the live data behind this article on ORTEX.
Open TBRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
